Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study.
Identifieur interne : 001532 ( PubMed/Corpus ); précédent : 001531; suivant : 001533Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study.
Auteurs : Mark C. Gillies ; Vuong Nguyen ; Vincent Daien ; Jennifer J. Arnold ; Nigel Morlet ; Daniel BarthelmesSource :
- Ophthalmology [ 1549-4713 ] ; 2016.
English descriptors
- KwdEn :
- Aged, Aged, 80 and over, Angiogenesis Inhibitors (administration & dosage), Angiogenesis Inhibitors (therapeutic use), Drug Substitution, Female, Fluorescein Angiography, Humans, Intravitreal Injections, Male, Ranibizumab (administration & dosage), Ranibizumab (therapeutic use), Receptors, Vascular Endothelial Growth Factor (administration & dosage), Receptors, Vascular Endothelial Growth Factor (therapeutic use), Recombinant Fusion Proteins (administration & dosage), Recombinant Fusion Proteins (therapeutic use), Registries, Tomography, Optical Coherence, Treatment Outcome, Vascular Endothelial Growth Factor A (antagonists & inhibitors), Visual Acuity (physiology), Wet Macular Degeneration (diagnosis), Wet Macular Degeneration (drug therapy), Wet Macular Degeneration (physiopathology).
- MESH :
- chemical , administration & dosage : Angiogenesis Inhibitors, Ranibizumab, Receptors, Vascular Endothelial Growth Factor, Recombinant Fusion Proteins.
- chemical , antagonists & inhibitors : Vascular Endothelial Growth Factor A.
- chemical , therapeutic use : Angiogenesis Inhibitors, Ranibizumab, Receptors, Vascular Endothelial Growth Factor, Recombinant Fusion Proteins.
- diagnosis : Wet Macular Degeneration.
- drug therapy : Wet Macular Degeneration.
- physiology : Visual Acuity.
- physiopathology : Wet Macular Degeneration.
- Aged, Aged, 80 and over, Drug Substitution, Female, Fluorescein Angiography, Humans, Intravitreal Injections, Male, Registries, Tomography, Optical Coherence, Treatment Outcome.
Abstract
To directly compare visual acuity (VA) outcomes with ranibizumab vs. aflibercept for eyes with neovascular age-related macular degeneration (nAMD) treated in routine clinical practice.
DOI: 10.1016/j.ophtha.2016.08.016
PubMed: 27707549
Links to Exploration step
pubmed:27707549Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study.</title><author><name sortKey="Gillies, Mark C" sort="Gillies, Mark C" uniqKey="Gillies M" first="Mark C" last="Gillies">Mark C. Gillies</name><affiliation><nlm:affiliation>The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Nguyen, Vuong" sort="Nguyen, Vuong" uniqKey="Nguyen V" first="Vuong" last="Nguyen">Vuong Nguyen</name><affiliation><nlm:affiliation>The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Daien, Vincent" sort="Daien, Vincent" uniqKey="Daien V" first="Vincent" last="Daien">Vincent Daien</name><affiliation><nlm:affiliation>The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, Australia; Department of Ophthalmology, Gui De Chauliac Hospital, Montpellier, France; Inserm, U1061, Montpellier, France. Electronic address: vincent.daien@sydney.edu.au.</nlm:affiliation></affiliation></author><author><name sortKey="Arnold, Jennifer J" sort="Arnold, Jennifer J" uniqKey="Arnold J" first="Jennifer J" last="Arnold">Jennifer J. Arnold</name><affiliation><nlm:affiliation>Marsden Eye Specialists, Parramatta, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Morlet, Nigel" sort="Morlet, Nigel" uniqKey="Morlet N" first="Nigel" last="Morlet">Nigel Morlet</name><affiliation><nlm:affiliation>Department of Population Health, University of Western Australia, Perth, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Barthelmes, Daniel" sort="Barthelmes, Daniel" uniqKey="Barthelmes D" first="Daniel" last="Barthelmes">Daniel Barthelmes</name><affiliation><nlm:affiliation>The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, Australia; Department of Ophthalmology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27707549</idno><idno type="pmid">27707549</idno><idno type="doi">10.1016/j.ophtha.2016.08.016</idno><idno type="wicri:Area/PubMed/Corpus">001532</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001532</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study.</title><author><name sortKey="Gillies, Mark C" sort="Gillies, Mark C" uniqKey="Gillies M" first="Mark C" last="Gillies">Mark C. Gillies</name><affiliation><nlm:affiliation>The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Nguyen, Vuong" sort="Nguyen, Vuong" uniqKey="Nguyen V" first="Vuong" last="Nguyen">Vuong Nguyen</name><affiliation><nlm:affiliation>The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Daien, Vincent" sort="Daien, Vincent" uniqKey="Daien V" first="Vincent" last="Daien">Vincent Daien</name><affiliation><nlm:affiliation>The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, Australia; Department of Ophthalmology, Gui De Chauliac Hospital, Montpellier, France; Inserm, U1061, Montpellier, France. Electronic address: vincent.daien@sydney.edu.au.</nlm:affiliation></affiliation></author><author><name sortKey="Arnold, Jennifer J" sort="Arnold, Jennifer J" uniqKey="Arnold J" first="Jennifer J" last="Arnold">Jennifer J. Arnold</name><affiliation><nlm:affiliation>Marsden Eye Specialists, Parramatta, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Morlet, Nigel" sort="Morlet, Nigel" uniqKey="Morlet N" first="Nigel" last="Morlet">Nigel Morlet</name><affiliation><nlm:affiliation>Department of Population Health, University of Western Australia, Perth, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Barthelmes, Daniel" sort="Barthelmes, Daniel" uniqKey="Barthelmes D" first="Daniel" last="Barthelmes">Daniel Barthelmes</name><affiliation><nlm:affiliation>The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, Australia; Department of Ophthalmology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Ophthalmology</title><idno type="eISSN">1549-4713</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Angiogenesis Inhibitors (administration & dosage)</term><term>Angiogenesis Inhibitors (therapeutic use)</term><term>Drug Substitution</term><term>Female</term><term>Fluorescein Angiography</term><term>Humans</term><term>Intravitreal Injections</term><term>Male</term><term>Ranibizumab (administration & dosage)</term><term>Ranibizumab (therapeutic use)</term><term>Receptors, Vascular Endothelial Growth Factor (administration & dosage)</term><term>Receptors, Vascular Endothelial Growth Factor (therapeutic use)</term><term>Recombinant Fusion Proteins (administration & dosage)</term><term>Recombinant Fusion Proteins (therapeutic use)</term><term>Registries</term><term>Tomography, Optical Coherence</term><term>Treatment Outcome</term><term>Vascular Endothelial Growth Factor A (antagonists & inhibitors)</term><term>Visual Acuity (physiology)</term><term>Wet Macular Degeneration (diagnosis)</term><term>Wet Macular Degeneration (drug therapy)</term><term>Wet Macular Degeneration (physiopathology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Angiogenesis Inhibitors</term><term>Ranibizumab</term><term>Receptors, Vascular Endothelial Growth Factor</term><term>Recombinant Fusion Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Vascular Endothelial Growth Factor A</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Angiogenesis Inhibitors</term><term>Ranibizumab</term><term>Receptors, Vascular Endothelial Growth Factor</term><term>Recombinant Fusion Proteins</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Wet Macular Degeneration</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Wet Macular Degeneration</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Visual Acuity</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Wet Macular Degeneration</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Drug Substitution</term><term>Female</term><term>Fluorescein Angiography</term><term>Humans</term><term>Intravitreal Injections</term><term>Male</term><term>Registries</term><term>Tomography, Optical Coherence</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To directly compare visual acuity (VA) outcomes with ranibizumab vs. aflibercept for eyes with neovascular age-related macular degeneration (nAMD) treated in routine clinical practice.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27707549</PMID><DateCreated><Year>2016</Year><Month>10</Month><Day>06</Day></DateCreated><DateCompleted><Year>2017</Year><Month>06</Month><Day>26</Day></DateCompleted><DateRevised><Year>2017</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1549-4713</ISSN><JournalIssue CitedMedium="Internet"><Volume>123</Volume><Issue>12</Issue><PubDate><Year>2016</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Ophthalmology</Title><ISOAbbreviation>Ophthalmology</ISOAbbreviation></Journal><ArticleTitle>Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study.</ArticleTitle><Pagination><MedlinePgn>2545-2553</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0161-6420(16)30913-7</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ophtha.2016.08.016</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To directly compare visual acuity (VA) outcomes with ranibizumab vs. aflibercept for eyes with neovascular age-related macular degeneration (nAMD) treated in routine clinical practice.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Database observational study.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Treatment-naïve eyes with nAMD tracked by the Fight Retinal Blindness outcome registry that commenced anti-vascular endothelial growth factor therapy with ranibizumab or aflibercept between December 1, 2013, and January 31, 2015. Eyes were matched at baseline for VA, age, and choroidal neovascular membrane (CNV) size.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Locally weighted scatterplot smoothing curves were used to display VA results. Eyes that switched or discontinued treatment were included with their last observation carried forward.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Change in mean VA (number of letters read on a logarithm of the minimum angle of resolution chart); number of injections and visits; proportion of eyes with inactive CNV over 12 months.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We identified 394 eyes (197 treated with ranibizumab and 197 with aflibercept) from 372 patients who received treatment from 34 practitioners. Baseline parameters were well matched. The mean (standard deviation [SD]) VA of ranibizumab-treated eyes increased from 58.6 (20.3) letters at baseline to 62.3 (23.9) (+3.7 [95% confidence interval {CI} 1.4-6.1]) letters (P = 0.001), compared with 58.9 (19.2) letters at baseline to 63.1 (21.5) (+4.26 [95% CI 2.0-6.5]) letters (P < 0.001) for eyes receiving aflibercept. The difference in change in crude VA of 0.6 letters between the 2 groups was not statistically significant (P = 0.76), nor was the difference in adjusted mean VA of the 2 groups (P = 0.26). In completers, the mean (SD) numbers of injections (8.1 [2.1] vs. 8.0 [2.3]; P = 0.27) and visits (9.6 [3.0] vs. 9.5 [3.1]; P = 0.15) did not differ between the 2 groups. The adjusted proportion of eyes in which the CNV lesion was graded as inactive during the study was similar between the eyes receiving ranibizumab and aflibercept (74% vs. 77%, respectively; P = 0.63).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Visual acuity outcomes at 12 months did not differ between ranibizumab and aflibercept used for nAMD in this large observational study, nor was a difference in treatment frequency found.</AbstractText><CopyrightInformation>Copyright © 2016 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gillies</LastName><ForeName>Mark C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Vuong</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daien</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, Australia; Department of Ophthalmology, Gui De Chauliac Hospital, Montpellier, France; Inserm, U1061, Montpellier, France. Electronic address: vincent.daien@sydney.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arnold</LastName><ForeName>Jennifer J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Marsden Eye Specialists, Parramatta, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morlet</LastName><ForeName>Nigel</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Population Health, University of Western Australia, Perth, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barthelmes</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, Australia; Department of Ophthalmology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ophthalmology</MedlineTA><NlmUniqueID>7802443</NlmUniqueID><ISSNLinking>0161-6420</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020533">Angiogenesis Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C467484">VEGFA protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance></Chemical><Chemical><RegistryNumber>15C2VL427D</RegistryNumber><NameOfSubstance UI="C533178">aflibercept</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D040262">Receptors, Vascular Endothelial Growth Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>ZL1R02VT79</RegistryNumber><NameOfSubstance UI="D000069579">Ranibizumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020533" MajorTopicYN="N">Angiogenesis Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057915" MajorTopicYN="N">Drug Substitution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005451" MajorTopicYN="N">Fluorescein Angiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058449" MajorTopicYN="N">Intravitreal Injections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069579" MajorTopicYN="N">Ranibizumab</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040262" MajorTopicYN="N">Receptors, Vascular Endothelial Growth Factor</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D041623" MajorTopicYN="N">Tomography, Optical Coherence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042461" MajorTopicYN="N">Vascular Endothelial Growth Factor A</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014792" MajorTopicYN="N">Visual Acuity</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057135" MajorTopicYN="N">Wet Macular Degeneration</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>06</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>08</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>08</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27707549</ArticleId><ArticleId IdType="pii">S0161-6420(16)30913-7</ArticleId><ArticleId IdType="doi">10.1016/j.ophtha.2016.08.016</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001532 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001532 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:27707549
|texte= Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:27707549" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |